Concizumab approved to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with haemophilia A or B with inhibitors

As with any medicine, the MHRA will keep the safety and effectiveness of mirdametinib under close review. 

The call for application for phase 2 of the AI Airlock is now open. This page contains information on eligibility and how to apply

MHRA launches a consultation on indefinite recognition of CE-marked medical devices  

List of Field Safety Notices from 13 to 17 October 2025.

Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.

Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.